IAVI at AIDS 2022

IAVI is proud to participate in AIDS 2022 hosted by the International AIDS Society (IAS). The conference will feature updates in HIV science, indigenous responses to HIV, youth-led initiatives, surveillance ethics, health innovation, mental health, equitable product rollout, HIV cure and vaccine research, and much more. We are eager to join in celebrating the progress made by scientists, advocates, and communities, and to engage in discussions and deliberations on how we will achieve a world without AIDS.

Below are the ways we are contributing to AIDS 2022, together with our partners. Learn more about the conference and register here to access conference presentations. And while the conference is happening, follow along on IAVI’s social media channels for updates and a window into the live event at #AIDS2022.

We gratefully acknowledge the funders whose generous support enables the IAVI and partner work being showcased at AIDS 2022.

Satellite, Symposium, and Oral Abstract Sessions

Thursday, July 28, 11:30 – 12:30 EDT

Pre-conference session: Future Leaders in HIV Economics: Assessing Equity, Cost-Effectiveness, Research Gaps and Policy Uptake in HIV Prevention

Presentation title: Biomedical prevention technologies: identifying gaps and proposing priorities for future research, Sergio Torres-Rueda, research fellow in health economics, London School of Hygiene and Tropical Medicine, France

Code PC32, Live (in-person)

IAVI author: Shelly Malhotra, executive director of Global Access, IAVI, United States

Friday, July 29, 14:45 – 16:15 EDT

Satellite session: Experimental medicine trials in Africa: ethical considerations and community engagement

Introduction: Robin Shattock, professor of mucosal infection and immunity, Imperial College London, United Kingdom

Code SA02301, Live (in-person)

Presentation title: Experimental Medicine Vaccine Trials, Kundai Chinyenze, executive medical director, IAVI, United Kingdom

Code SA02302, Live (hybrid)

Panel discussion: Eunice Nduati, principal investigator, KEMRI | Wellcome Trust, Kenya

Code SA02304, Live (in-person)

Friday, July 29, 14:45 – 16:15 EDT

Satellite session: Africa HIV cure research: Strengthening industry-community engagement in clinical research

Presentation title: How clinical research is involving communities, Thumbi Ndung’u, scientific director, University of KwaZulu-Natal HIV Pathogenesis Programme (HPP), South Africa

Code SA02705, Pre-recorded by the speaker

Panel discussion and Q&A: Thumbi Ndung’u, scientific director, University of KwaZulu-Natal HIV Pathogenesis Programme (HPP), South Africa

Code SA02707, Live (in-person)

Saturday, July 30, 8:00 – 9:00 EDT

Satellite session: Will mRNA lead to a long-awaited HIV vaccine?

Presentation title: IAVI/Moderna studies (G001, G002, G003), William Schief, executive director of vaccine design, IAVI’s Neutralizing Antibody Center (NAC), United States

Code SA04602, Live (hybrid)

Panel discussion: Julien Nyombayire, research physician, Center for Family Health Research, Rwanda

Code SA04605, Live (in-person)

Sunday, July 31, 14:15 – 15:15 EDT

Symposium: Combining immunotherapeutic agents to achieve ARV-free remission of HIV

Session track: Track A: Basic and translational science, Thumbi Ndung’u, scientific director, University of KwaZulu-Natal HIV Pathogenesis Programme (HPP), South Africa

Code SY20, Live (hybrid)

Sunday, July 31, 14:15 – 15:15 EDT

Symposium: Antibodies for HIV prevention: The path forward

Introduction: Introductory notes on why we need to consider mAbs as a potential tool for HIV prevention, Shelly Malhotra, executive director of Global Access, IAVI, United States

Presentation title: Can we design, develop and manufacture antibodies that are effective, affordable and easy to deliver? Evidence from the pipeline, Devin Sok, vice president of discovery and innovation, IAVI, United States

Code SY21, Live (hybrid)

Monday, August 1, 14:15 – 15:15 EDT

Oral abstract session and Q&A: Optimizing investments for health: Cash, cost and prices

Presentation title: Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for all infants born in high-burden settings, Caitlin M. Dugdale, infectious disease physician and research fellow, Massachusetts General Hospital, Medical Practice Evaluation Center, United States

Code OAE03, Live (hybrid)

IAVI authors: Shelly Malhotra, executive director of Global Access, IAVI, United States and Vincent Muturi-Kioi, medical director, IAVI, Kenya

Global Village

If you are attending the conference, the Global Village will be a great place to visit to broaden your networks, engage in exhibits, and learn from community led initiatives addressing AIDS. The Global Village will host speaker sessions, cultural activities, live performances, film screenings, art exhibitions, and more.

Posters

Additionally, many researchers are representing IAVI, ADVANCE, and partners in the posters listed below.